Vasily Shuvaev
About
In The Last Decade
Vasily Shuvaev
40 papers receiving 242 citations
Peers
Comparison fields: 5 of 26
- Hematology 232
- Genetics 211
- Rheumatology 104
- Oncology 54
- Molecular Biology 40
Countries citing papers authored by Vasily Shuvaev
This map shows the geographic impact of Vasily Shuvaev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vasily Shuvaev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vasily Shuvaev more than expected).
Fields of papers citing papers by Vasily Shuvaev
This network shows the impact of papers produced by Vasily Shuvaev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vasily Shuvaev. The network helps show where Vasily Shuvaev may publish in the future.
Co-authorship network of co-authors of Vasily Shuvaev
This figure shows the co-authorship network connecting the top 25 collaborators of Vasily Shuvaev. A scholar is included among the top collaborators of Vasily Shuvaev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vasily Shuvaev. Vasily Shuvaev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 0 | |
| 3 | 0 | |
| 4 | 2 | |
| 5 | 2 | |
| 6 | 1 | |
| 7 | 0 | |
| 8 | 3 | |
| 9 | 0 | |
| 10 | PHARMACOECONOMIC MODELLING OF TARGET THERAPY CHRONIC MYELOGENOUS LEUKEMIA: EARLY AND LATE SWITCHING | 1 |
| 11 | Primary myelofibrosis: own experience and news from diagnostic and treatment | 1 |
| 12 | 5 | |
| 13 | 0 | |
| 14 | 1 | |
| 15 | 10 | |
| 16 | 1 | |
| 17 | Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients | 1 |
| 18 | 2 | |
| 19 | 1 | |
| 20 | PRIMARY MYELOFIBROSIS - A SURVEY BASED ON THE 20-YEARS' EXPERIENCE OF A SINGLE CENTER | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.